RASSF1 and breast carcinoma: Detailed analysis of the RASSF1 promoter (RASSF1‐1α vs RASSF1‐2γ) in early‐stage breast cancer supports the association of RASSF1C with adverse prognosis and offers an optimized biomarker for patients.